Research Article
Open Access
Evaluation of Radiosurgery Target Volume
Determination for Meningiomas Based on Computed
Tomography (CT)
And Magnetic Resonance Imaging (MRI)
Omer Sager1, Ferrat Dincoglan1, Selcuk Demiral1, Murat Beyzadeoglu1
1Department of Radiation Oncology; University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey
*Corresponding author: Omer Sager, University of Health Sciences, Gulhane Medical Faculty, Department of Radiation Oncology, Gn.Tevfik Saglam Cad. 06018, Etlik, Kecioren, Ankara, Turkey, E-mail:
@
Received: January 02, 2019; Accepted: January 18, 2019; Published: January 29, 2019
Citation: Omer S, Ferrat D, Demiral S, Murat B (2019) Evaluation of Radiosurgery Target Volume Determination for Meningiomas Based on Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Cancer Sci Res Open Access 5(2): 1-4. DOI: 10.15226/csroa.2018.00147
Abstract
Objective: Meningiomas arise from arachnoid cap cells and
comprise the commonest benign tumor of the brain, accounting
for more than one third of all intracranial neoplasms. Surgery and
radiation therapy (RT) have been traditionally used in meningioma
management. Radiosurgery is a sophisticated form of therapeutic
irradiation with the capability of delivering high doses of radiation
to well defined targets with typically steep dose gradients around the
treatment volumes under robust stereotactic localization and image
guidance. Target volume definition is an important part of menigioma
radiosurgery. In this study, we assessed the use of multimodality
imaging for target volume definition in radiosurgery of meningiomas.
Methodology: We included 27 patients receiving meningioma radiosurgery at our department. All patients were treated with high precision radiosurgery after multidisciplinary assessment of patients regarding lesion size, location, association with critical neurovascular structures, symptomatology, and previous treatments. Target volume determination was done based on using only CT images and also by incorporation of MR fusion to perform a comparative assessment.
Results: Comparative evaluation revealed improved target volume definition by incorporation of MRI into radiosurgery treatment planning for patients treated with radiosurgery for meningiomas.
Conclusion: Improved target definition is a pertinent goal of optimal radiosurgical treatment planning. Our study supports the utility of MRI in meningioma radiosurgery treatment planning. Clearly, further research is warranted to refine target definition for radiosurgical management of meningiomas.
Key words: Meningioma; Radiosurgery; Magnetic Resonance Imaging (MRI)
Methodology: We included 27 patients receiving meningioma radiosurgery at our department. All patients were treated with high precision radiosurgery after multidisciplinary assessment of patients regarding lesion size, location, association with critical neurovascular structures, symptomatology, and previous treatments. Target volume determination was done based on using only CT images and also by incorporation of MR fusion to perform a comparative assessment.
Results: Comparative evaluation revealed improved target volume definition by incorporation of MRI into radiosurgery treatment planning for patients treated with radiosurgery for meningiomas.
Conclusion: Improved target definition is a pertinent goal of optimal radiosurgical treatment planning. Our study supports the utility of MRI in meningioma radiosurgery treatment planning. Clearly, further research is warranted to refine target definition for radiosurgical management of meningiomas.
Key words: Meningioma; Radiosurgery; Magnetic Resonance Imaging (MRI)
Introduction
Meningiomas arise from arachnoid cap cells and comprise
the commonest benign tumor of the brain, accounting for more
than one third of all intracranial neoplasms [1,2]. Meningiomas
are typically benign tumors with an indolent disease course in
the majority of patients, however, they may also cause severe
symptoms depending on their location and association with
nearby critical structures. Meningiomas may be located at
several locations in the brain including the cavernous sinus,
foramen magnum, cerebellopontine angle, olfactory groove,
cerebral convexities, parasagittal/falx cerebri, intraventricular,
intraorbital, sphenoid wing, petrous ridge, suprasellar region,
tentorium, and posterior fossa. World Health Organization
(WHO) classification is widely used for meningiomas. Benign,
WHO grade I meningioma subtypes include the meningothelial,
psammomatous, fibrous, transitional, secretory, microcystic,
metaplastic, and lymphoplasmocyte-rich types [3]. WHO grade
II and WHO grade III meningiomas have a lower incidence [3,4].
WHO grade II meningiomas include the chordoid, clear cell,
and atypical meningiomas [3,4].WHO grade III meningiomas
include the rhabdoid, papillary, and anaplastic types [3,4]. Due
to the benign and indolent nature of the majority of menigiomas,
a considerable number of patients may be observed with
any intervention reserved for progression and occurrence of
symptomatology. Nevertheless, meningiomas may cause a
wide spectrum of symptoms depending on their location and
association with critical neurovascular structures. Surgery
and radiation therapy (RT) have been traditionally used in
meningioma management [5]. Complete surgical removal has
been standard if feasible, resulting in prompt resolution of
meningioma related symptoms. RT plays a central role as a
complementary or definitive treatment modality. Higher grade
meningiomas have a high tendency for recurrence even after
comprehensive surgical resection, which renders adjuvant RT a
viable adjuvant therapeutic option for these patients [5]. A recent
study has supported the use of RT for management of newly
diagnosed WHO grade II meningiomas after gross total resection
and for management of recurrent WHO grade I meningiomas to
achieve improved local control [6].
Radiosurgery in the forms of Stereotactic Radiosurgery (SRS), Fractionated Stereotactic Radiotherapy (FSRT), Hypofractionated Stereotactic Radiotherapy (HFSRT), and Stereotactic Body Radiation Therapy (SBRT) has emerged as a viable radiotherapeutic modality for management several benign and malign tumors throughout the human body including meningiomas, brain metastases, arteriovenous malformations, pituitary adenomas, vestibular schwannomas, cerebral cavernous malformations, craniopharyngiomas, glomus jugulare tumors, pulmonary oligometastases, and recurrent glioblastomas [7-25].
Primary advantage of radiosurgery is the ability to deliver high dose of radiation to well defined targets with typically steep dose gradients around the treatment volume under robust stereotactic localization and image guidance. This contemporary treatment modality offers high precision management of several intracranial and extracranial tumors with a condensed treatment schedule along with a favorable toxicity profile. In the context of meningiomas, several studies have reported the safety and efficacy of radiosurgery as a complementary and definitive treatment modality for meningiomas [14,23,25-27].
Target volume definition plays a central role in radiosurgical treatments. Multimodality imaging may be utilized for determining radiosurgery treatment volumes [28]. For radiotherapeutic management of meningiomas, Magnetic Resonance Imaging (MRI) has been utilized for several purposes including detection, localization and target definition, lesion characterization, differentiation of meningioma grades based on imaging features, prediction of clinical agressiveness, assessment of treatment response and prognosis [29-36]. In this context, we evaluated the incorporation of Magnetic Resonance Imaging (MRI) into target volume definition for radiosurgery of meningiomas in this study.
Radiosurgery in the forms of Stereotactic Radiosurgery (SRS), Fractionated Stereotactic Radiotherapy (FSRT), Hypofractionated Stereotactic Radiotherapy (HFSRT), and Stereotactic Body Radiation Therapy (SBRT) has emerged as a viable radiotherapeutic modality for management several benign and malign tumors throughout the human body including meningiomas, brain metastases, arteriovenous malformations, pituitary adenomas, vestibular schwannomas, cerebral cavernous malformations, craniopharyngiomas, glomus jugulare tumors, pulmonary oligometastases, and recurrent glioblastomas [7-25].
Primary advantage of radiosurgery is the ability to deliver high dose of radiation to well defined targets with typically steep dose gradients around the treatment volume under robust stereotactic localization and image guidance. This contemporary treatment modality offers high precision management of several intracranial and extracranial tumors with a condensed treatment schedule along with a favorable toxicity profile. In the context of meningiomas, several studies have reported the safety and efficacy of radiosurgery as a complementary and definitive treatment modality for meningiomas [14,23,25-27].
Target volume definition plays a central role in radiosurgical treatments. Multimodality imaging may be utilized for determining radiosurgery treatment volumes [28]. For radiotherapeutic management of meningiomas, Magnetic Resonance Imaging (MRI) has been utilized for several purposes including detection, localization and target definition, lesion characterization, differentiation of meningioma grades based on imaging features, prediction of clinical agressiveness, assessment of treatment response and prognosis [29-36]. In this context, we evaluated the incorporation of Magnetic Resonance Imaging (MRI) into target volume definition for radiosurgery of meningiomas in this study.
Materials and Methods
We identified 27 patients receiving meningioma radiosurgery
at our department. All patients were treated with high
precision radiosurgery after multidisciplinary assessment of
patients regarding lesion size, location, association with critical
neurovascular structures, symptomatology, and previous
treatments. Computed Tomography (CT) simulation was
performed at the CT simulator (GE Lightspeed RT, GE Healthcare,
Chalfont St. Giles, UK) at our department under stereoactic
immobilization. Slice thickness was 1.25 for acquiring the
planning images at the CT simulator, while a thin slice MRI was also
performed for all patients using 1 mm slice thickness, typically
within one week before radiosurgical treatment. CT simulation
images were transferred to the contouring workstation (SimMD,
GE, UK) for delineation of target volume and surrounding critical
organs. Target volume determination was done based on using
only CT images and also by incorporation of MR fusion to perform
a comparative assessment. Determination of ground truth
target volume for actual treatment and comparison purposes
was performed by the expert group of treating physicians after
thorough evaluation, collaboration and consensus using data from
both CT and MRI. While ERGO ++ (CMS, Elekta, UK) treatment
planning system was used for radiosurgery planning, treatments
were delivered using Synergy (Elekta, UK) Linear Accelerator
(LINAC) under stereotactic localization and image guidance with
kV-CBCT (kilovoltage Cone Beam CT) and XVI (X-ray Volumetric
Imaging, Elekta, UK).
Results
A total of 27 patients were included in the analysis. Median
target volume was 8.1 cc (range: 2.3-31.8 cc) with CT-only
imaging, 8.6 cc (range: 2.4-32.7 cc) with CT-MR fusion based
imaging, and 8.5 cc (range: 2.4-32.5 cc) on consensus decision
of all treating physicians with collaborative comprehensive
assessment and colleague peer review. The ground truth target
volumes decided by the expert group of treating physicians after
thorough evaluation, collaboration and consensus using data
from both CT and MRI were consistent with target definition
based on CT-MR fusion based imaging in majority of the patients,
and incorporation of MR images resulted in improved delineation
of the meningioma lesions with less interobserver variability.
Figure 1 illustrates planning CT and MR images of a patient with
meningioma.
Figure 1:Planning CT and MR images of a patient with meningioma
Discussion
Decision making for optimal treatment of meningiomas
requires close collaboration among experts in neurosurgery,
neuroradiology, and radiation oncology. Individual evaluation
should be performed by the multidisciplinary team considering
lesion size and location, association with critical neurovascular
structures, patient age, availability of resources, logistical
issues, patient symptomatology and preferences. If treatment
with radiosurgery is decided, vigilance is required for target
volume determination since radiosurgical treatments typically
deliver high fractional doses for local control of the meningioma
lesions. Precision in target definition is warranted to achieve an
improved toxicity profile along with durable local control. In this
context, multimodality imaging may facilitate accurate targeting
through providing improved contrast resolution. MRI may add
to the accuracy of contouring the meningioma lesions. While CT
achieves improved assessment of bony anatomy, MRI remains to
be a viable imaging modality for identification of the dural tail in
meningiomas.
Conclusion
Improved target definition is a pertinent goal of optimal
radiosurgical treatment planning. Our study supports the utility
of MRI in meningioma radiosurgery treatment planning. Clearly,
further research is warranted to refine target definition for
radiosurgical management of meningiomas.
ReferencesTop
- Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18(suppl_5):v1-v75. doi: 10.1093/neuonc/now207
- Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314. doi: 10.1007/s11060-010-0386-3
- Harter PN, Braun Y, Plate KH. Classification of meningiomas-advances and controversies. Chin Clin Oncol. 2017;6(Suppl 1):S2. doi: 10.21037/cco.2017.05.02
- Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS.Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015;17(8):1166-1173. doi: 10.1093/neuonc/nov069
- Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4-23. doi: 10.3171/2014.7.JNS131644
- Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018;129(1):35-47. doi: 10.3171/2016.11.JNS161170
- Sirin S, Oysul K, Surenkok S, Sager O, Dincoglan F, Dirican B, et al. Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience. Vojnosanit Pregl. 2011;68(11):961-966.
- Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Sirin S, Surenkok S, et al. Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis. Tumori. 2012;98(5):630-635. doi: 10.1700/1190.13205
- Dincoglan F, Sager O, Gamsiz H, Demiral S, Uysal B. Management of arteriovenous malformations by stereotactic radiosurgery: A single center experience. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi. 2012;22(2): 107-112.
- Surenkok S, Sager O, Dincoglan F, Gamsiz H, Demiral S, Uysal B, et al. Stereotactic radiosurgery in pituitary adenomas: A single center experience. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi. 2012;22(4): 255-260.
- Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. Stereotactic radiosurgery for intracranial tumors: A single center experience. Gulhane Med J. 2012;54(3):190-198.
- Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: A single center experience. Tumori. 2013;99(5):617-622. doi: 10.1700/1377.15312
- Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, Sager O, et al. Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. Neoplasma. 2013;60(3):322-327. doi: 10.4149/neo_2013_043
- Dincoglan F, Beyzadeoglu M, Sager O, Uysal B, Demiral S, Gamsiz H, et al. Evaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: A single center experience. J BUON. 2013;18(3):717-722.
- Sager O, Beyzadeoglu M, Dincoglan F, Uysal B, Gamsiz H, Demiral S, et al. Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: A 15-year single-center experience. Ann Saudi Med. 2014;34(1):54-58. doi: 10.5144/0256-4947.2014.54
- Sager O, Beyzadeoglu M, Dincoglan F, Gamsiz H, Demiral S, Uysal B, et al. Evaluation of linear accelerator-based stereotactic radiosurgery in the management of glomus jugulare tumors. Tumori. 2014;100(2):184-188. doi: 10.1700/1491.16409
- Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, Oysul K, et al. Management of patients with ≥ 4 brain metastases using stereotactic radiosurgery boost after whole brain irradiation. Tumori. 2014;100(3):302-306. doi: 10.1700/1578.17210
- Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, Uysal B, et al. Evaluation of linear accelerator (linac)-based stereotactic radiosurgery (srs) for the treatment of craniopharyngiomas. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi. 2014;24(2):123-129.
- Gamsiz H, Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, Uysal B, et al. Management of pulmonary oligometastases by stereotactic body radiotherapy. Tumori. 2014;100(2):179-183. doi: 10.1700/1491.16407
- Sager O, Dincoglan F, Beyzadeoglu M. Stereotactic radiosurgery of glomus jugulare tumors: Current concepts, recent advances and future perspectives. CNS Oncol. 2015;4(2):105-114. doi: 10.2217/cns.14.56
- Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, Uysal B, et al. Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. Tumori. 2015;101(1):98-103. doi: 10.5301/tj.5000222
- Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, Uysal B, et al. Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. Tumori. 2015;101(2):179-184. doi: 10.5301/tj.5000236
- Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, Gundem E, et al. Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM). Jpn J Radiol. 2016;34(11):730-737.
- Dincoglan F, Sager O, Demiral S, Uysal B, Gamsiz H, Dirican B, et al. Radiosurgery for recurrent glioblastoma: A review article. Neurol Disord Therap. 2017;1(4):1-5.
- Demiral S, Dincoglan F, Sager O, Uysal B, Gamsiz H, Ozcan F, et al. Contemporary Management of Meningiomas with Radiosurgery. Int J Radiol Imaging Technol. 2018;4(2):041. doi: 10.23937/2572-3235.1510041
- Koga T, Shin M, Saito N. Role of γ knife radiosurgery in neurosurgery: past and future perspectives. Neurol Med Chir (Tokyo). 2010;50(9):737-748.
- Pollock BE, Stafford SL, Link MJ. Stereotactic radiosurgery of intracranial meningiomas. Neurosurg Clin N Am. 2013;24(4):499-507. doi: 10.1016/j.nec.2013.05.006
- Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, Dirican B, et al. Evaluation of Target Volume Determination for Single Session Stereotactic Radiosurgery (SRS) of Brain Metastases. Canc Therapy & Oncol Int J. 2018;12(5): 555848. doi: 10.19080/CTOIJ.2018.12.555848
- Watts J, Box G, Galvin A, Brotchie P, Trost N, Sutherland T. Magnetic resonance imaging of meningiomas: a pictorial review. Insights Imaging. 2014;5(1):113-122. doi: 10.1007/s13244-013-0302-4
- Hale AT, Wang L, Strother MK, Chambless LB. Differentiating meningioma grade by imaging features on magnetic resonance imaging. J Clin Neurosci. 2018;48:71-75. doi: 10.1016/j.jocn.2017.11.013
- Shimol EB, Joskowicz L, Eliahou R, Shoshan Y. Computer-based radiological longitudinal evaluation of meningiomas following stereotactic radiosurgery. Int J Comput Assist Radiol Surg. 2018;13(2):215-228. doi: 10.1007/s11548-017-1673-7
- Cohen-Inbar O, Tata A, Moosa S, Lee CC, Sheehan JP. Stereotactic radiosurgery in the treatment of parasellar meningiomas: long-term volumetric evaluation. J Neurosurg. 2018;128(2):362-372. doi: 10.3171/2016.11.JNS161402
- Surov A, Ginat DT, Sanverdi E, Lim CC, Hakyemez B, Yogi A, et al. Use of Diffusion Weighted Imaging in Differentiating Between Maligant and Benign Meningiomas. A Multicenter Analysis. World Neurosurg. 2016;88:598-602. doi: 10.1016/j.wneu.2015.10.049
- Tamrazi B, Shiroishi MS, Liu CS. Advanced Imaging of Intracranial Meningiomas. Neurosurg Clin N Am. 2016;27(2):137-43. doi: 10.1016/j.nec.2015.11.004
- Varlotto J, Flickinger J, Pavelic MT, Specht CS, Sheehan JM, Timek DT, et al. Distinguishing grade I meningioma from higher grade meningiomas without biopsy. Oncotarget. 2015;6(35):38421–38428. doi: 10.18632/oncotarget.5376
- Zikou A, Alexiou GA, Goussia A, Kosta P, Xydis V, Voulgaris S, et al. The role of diffusion tensor imaging and dynamic susceptibility perfusion MRI in the evaluation of meningioma grade and subtype. Clin Neurol Neurosurg. 2016;146:109-115. doi: 10.1016/j.clineuro.2016.05.005